| COG-AALLO1P2 | (an outline on this site) | completed | II | 1/03 to 12/05 | bone marrow relapse, induction therapy |
| COG-AALLO2P2 | (an outline on this site) | active | not specified | 11/2004-present | late EM relapse |
| COG-AALL0433 | cancer.gov outline | active | III | 2007-2011 | intermediate risk: bone marrow >36months after initial dx; combined BM and EM >36 months; isolated EM relapse less than 18 months after initial dx |
| COG-ADVL04P2 | cancer.gov outline | active | II | 2004-present | Epratuzumab Alone and in Combination With Re-Induction Combination Chemotherapy in Pediatric Patients With Relapsed CD22-Positive ALL. Epratuzumab is anti-CD22 monoclonal antibody. This trial is Epratuzumab combined with the backbone therapy of AALL01P2. |
| St. Judes ALLR17 | (a brief overview on this site) | active | II | 2003-present | covers all types of relapses |
| BFM ALL-REZ 2002 | ALL-REZ BFM 2002 | active | Protocol for the Treatment of Children with Relapsed Acute Lymphoblastic Leukemia also: www.clinicaltrials.gov/ct/gui/show/NCT00114348?order=1 |
||
| POG-9411 | cancer.gov outline | completed | II | 1995-7 | first marrow relapse regardless of time after dx, with or without EM relapse, or first EM relapse with M2 marrow; transplant vs aggressive chemotherapy |
| POG-9412 | cancer.gov outline | completed | II | 1996-2000 | isolated CNS relapse, regardless of time after dx |
| CCG-1941 | cancer.gov outline | completed | III | 1995-7(?) | bone marrow relapse while on frontline therapy or within a year of completion of frontline therapy |
| POG-9310 | cancer.gov outline | completed | II | 1993-4 | bone marrow/EM/combined relapse; escalating rotational drug therapy |
| POG-9061 | cancer.gov outline | completed | II, I | 1990-3 | isolated CNS relapse |
| BMTCTN-0501 | cancer.gov outline | active | III | 2006-present | Single- vs double-unit umbilical cord blood transplantation; for relapsed ALL, high-risk ALL, and Myelodysplastic Syndromes |
| FHCRC-1629.00 | cancer.gov outline | active | I, II | 2005-present | Fred Hutchinson: Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
| UKALL R2 | cancer.gov outline | closed | III | 1995-2002 | UK trial; Randomized Study of Unrelated Donor BMT vs Continuing Chemotherapy for Childhood Acute Lymphoblastic Leukemia in First Relapse |
| CCG-1951 | cancer.gov outline | closed | III | 1996- 2002 | Study of Systemic Chemotherapy Combined with Local Therapy for Isolated Extramedullary Relapse of Acute Lymphoblastic Leukemia |